This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk06: and welcome to the Azenta Q4 2023 financial results. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question-and-answer session. At that time, if you have a question, please press the 1 followed by the 4 on your telephone. If at any time during the conference you need to reach an operator, please press star 0. As a reminder, this conference is being recorded Monday, November 13, 2023. I will now turn the conference over to Sarah Silverman, Head of Investor Relations.
spk05: Thank you, Operator, and good afternoon to everyone on the line today. We would like to welcome you to our earnings conference call for the fourth quarter of fiscal year 2023. Our fourth quarter earnings press release was issued after the close of the market today and is available on our Investor Relations website located at investors.azenta.com in addition to the supplementary PowerPoint slides that will be used during the prepared remarks today. I would like to remind everyone that during the course of the call, we will be making a number of forward-looking statements within the meaning of the Private Litigation Securities Act of 1995. There are many factors that may cause actual financial results or other events to differ from those identified in such forward-looking statements. I refer you to the section of our earnings release titled Safe Harbor Statement, the Safe Harbor slide on the aforementioned PowerPoint presentation on our website, and our various filings with the SEC, including our annual reports on Form 10-K and our quarterly reports on Form 10-Q. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today. We may refer to a number of non-GAAP financial measures which are used in addition to and in conjunction with results presented in accordance with GAAP. We believe the non-GAAP measures provide an additional way of viewing aspects of our operations and performance, but when considered with the GAAP financial results and the reconciliation of GAAP measures, they provide an even more complete understanding of the events of business. Non-GAAP measures should not be relied upon to the exclusion of the GAAP measures themselves. On the call with me today is our President and Chief Executive Officer, Steve Schwartz, and our Chief Financial Officer, Herman Kudo. We will open the call with remarks from Steve on highlights of the fourth quarter. Then Herman will provide a more detailed look into our financial results and our outlook for fiscal year 2024. We will then take your questions at the end of the prepared remarks. With that, I would like to turn the call over to our CEO, Steve Schwartz.
spk10: Thank you, Sarah. Good afternoon, everyone, and thank you for joining us. Today, I'll direct my remarks to a summary of 2023 results and a preview of how we see 2024. including some of our key initiatives. As you've seen in our press releases today, we have a lot to talk about on this call. A strong fourth quarter result, a healthy outlook for fiscal 2024, a big order for V Medical Systems, as well as important implications for Go Forward Azenta, including a significant capital allocation commitment to share repurchases, as well as an announcement as part of our regular board refresh. So let's get to it. It's an exciting and energizing time for Zenta. We had a strong finish to fiscal 2023 with fourth quarter results coming in nicely on top and bottom line. We're pleased with the progress we've made during the quarter and our positioning headed into fiscal 2024. Fiscal 2023 was another transformative year for the company as we reached over $660 million in revenue. We accelerated and adjusted to the demands and opportunities afforded to an innovative standalone life sciences company We've taken substantial prudent actions to reinvigorate growth in revenue and profitability, even in what continues to be a challenging macroeconomic environment. We added key leadership and strategic sales expertise and restructured our commercial team to better focus on specific business lines and increase our coverage of geographies. We continue to build out our portfolio of unique offerings that deliver on our purpose to enable breakthroughs faster. We extended our strategic leverage and expanded our geographic footprint with the additions of B Medical and Zyeth. And as a standalone company after the divestiture of Brooks, we completed the first phase of streamlining cost reductions. There's much more work to be done, but we have a plan for continued execution in the coming year. Notably, we demonstrated positive adjusted free cash flow of $14 million in fiscal 2023, one measure of the progress we've made throughout the course of the year, and an indication of what this business is truly capable of as we go from here. And on October 1st, we moved to our new three-segment reporting structure of multi-omics, sample management solutions, and B Medical, which we believe will significantly improve our operating efficiency while better aligning our offerings to customer needs and providing greater transparency to our shareholders. Most importantly, we're a year better at all that we do and in the value we offer to our customers. Our capabilities continue to enable customers, and we're investing to stay ahead of their needs for solutions that shorten their time to discovery. Altogether, we believe we're extremely well positioned to continue to outgrow the market. And now for some highlights from the quarter. In Q4, we delivered revenue of $172 million, which translates to organic growth of 2% year over year, and 6% when you exclude our consumables and instruments business, which remains soft in line with market trends. Let's look at the business by segment. In services, we delivered fourth quarter organic growth of 1% year over year. Genomics was down 2% year over year, primarily driven by continued macroeconomic headwinds. From a regional perspective, in genomics, China was once again notably strong, delivering 12% organic growth. And although there's been a significant slowdown in the China economy post-COVID, we're still growing due to our strong customer relationships and continued share gains with new customers in the region. Despite the softer market environment, we believe our team has adapted extremely well to address customer needs, and that performance has been solid on a relative basis. Our sales realignment and strategic investments in sales expertise is proving to be the remedy we sought for our slower OMIC sales at the start of the year. We have more to do, but as the current organization gains traction, we're in for a return to solid growth in 2024. In the sample repository solutions business, we grew 9% year over year, led once again by growth in core storage. As we've previously announced, we're in the process of opening a new biorepository in the Boston area. We've received great customer interest, and we're currently in fit-up mode through the end of this calendar year. We look forward to accepting customer samples in early calendar 2024. Since we last spoke with you, we closed another large deal where we'll provide sample management and multi-omic services for prospective research study. Similar to our project with the Lupus Research Alliance, we're demonstrating the value of our sample management and sample measurement platform to provide data to researchers doing discovery. This is a multi-million dollar, multi-year partnership rooted in the strong relationship that we developed over many years in the sample repository side of the business. This win and others like it are a testament to the high quality capability set and reputation that we've built over the past decade. Moving now to products. The products business grew 3% year over year on an organic basis, led by record revenues in automated store systems. Store systems grew 38% year over year, driven by our large automated stores business, which we previously reported has accumulated significant backlog over the past few quarters. This team has done a tremendous job to engineer, deliver, and install these orders at customer sites at a record pace. In CNI, we did continue to see year-over-year headwinds, but the good news is that this business expanded sequentially for the first time since Q1 of this year. Finally, B Medical ended the year strong, delivering $29 million of Q4 revenue led by Cold Chain Solutions. For the full year, B Medical generated $113 million of revenue and was decretive to our earnings per share. B Medical is a differentiated market leader in the areas that it operates, in particular, vaccine cold chain, and it's profitable. What's more is that from the lens of Azenta ownership, we see meaningful strategic upside in expanding the scope and reach of cold chain projects. We're building our reputation as Azenta in fast-growing emerging markets and engaging with several opportunities that will leverage B Medical in the important chain to connect precious biological samples to researchers. One piece of exciting news I'd like to share today is about one of these transformative opportunities. Last week, we signed a memorandum of understanding with the Democratic Republic of Congo for a project to support in-country vaccination efforts. This project has the potential to generate approximately $60 million in our fiscal year 2024. Let me put this order into perspective on how it impacts our outlook for the year. On top of the $113 million we delivered in 23, we expect 24 to be a growth year for B Medical. Our guidance for the year comes from our view of the pipeline, which is richer than it's ever been. For the upsizing of the DRC deal, the pipeline already included a program from the DRC, but none of the magnitude we just described, and with it, gives us additional confidence in the outlook for B Medical's business. We have a healthy and growing pipeline, but revenue in 24 will be delivered with a different cadence than we've seen in the past, where historically Q1 was the largest quarter of the year. Keep in mind, the B medical business is agnostic to the macro environment, but it is lumpy. When we've guided inside a quarter, we've anchored on a forecast for which we have orders in hand, and our Q1 outlook is no different. We currently expect Q1 to be meaningfully down versus the prior year, but still delivering growth on a full year basis. Herman will provide more color in his prepared remarks. Let me say a little bit more about this DRC project and its strategic significance. It's important to note that this opportunity began as one that supported traditional vaccine cold chain solutions from B Medical, but because of Azenta, it's expanded in scope to form the first part of a critical country initiative that will also include the retrieval and processing of biological samples. Although this secondary part of the project is still being formed, it's one of the key tenets for why this engagement has come to Azenta and Be Medical. We're enthusiastic about the prospects for this meaningful human health initiative and our enabling role in this important mission. As we wrap up fiscal 2023 and move into 2024, I'd like to revisit our overarching strategy and vision for Azenta. As I think about the progression of the business over the past decade, we started as a life sciences tools and products company, later added sample management services, then genomics or multiomics as we now refer to it, and most recently emerging markets cold chain solutions. We stand here today as a truly unique end-to-end biosample management company with a platform that provides expertise from sample to answer, enabling our customers to accelerate breakthroughs and therapies. First and foremost, we're focused on strengthening our key leadership positions in the markets we serve, But we're also keen to leverage our end-to-end biosample management capabilities to drive the next vector of growth. While it's still early, I'd like to provide some insight into our plans, starting with the large deal in the Democratic Republic of Congo as the first live example. As Azentha, we're able to source biological samples from participants of certain phenotype, format them for storage and automated workflow analysis, keep them in safe, cold repositories and systems until they're to be interrogated for any of many multi-omics measurements. We then supply data on these samples to entities who focus on discoveries and cures. Our ability to manage this entire critical sample sourcing, storage, and measurement workflow chain is a unique and increasingly valuable capability for our customers. Today, most of the samples we handle are from participants of European descent And although valuable, there's tremendous interest in biological samples that are from contributors of non-European descent. But these samples are scarce because they're difficult to obtain, transport, and consent. We have the platform that will allow us not only to source these hard to collect samples, we'll also have a means to secure them in regions of interest, allow in-country research on these samples, and simultaneously permit access to those rare and valuable samples through our infrastructure. That's to say, we've developed a platform not only to manage and measure samples for others, which has already driven $650 million of business and still has tremendous growth upside, but we intend to use this unique platform to source and provide data on high-value biological samples to a multitude of interested partners. Hence, the power of our portfolio is clear. We utilize our cold chain care and management of samples, exercise our world-class scientific expertise to interrogate these samples, and deliver accurate data to discovery teams around the world. The untapped value opportunity of this platform is twofold. First, more customer samples as we tap into a market opportunity that we barely penetrate by bringing order to vast global collections of samples that have accumulated over decades. As we get better at what we do, customers are giving us more to do for them. Second, we can leverage our platform to be the source of high-value samples that are rare, meaning non-European, consented for use in research and discovery, highly annotated through multi-omics analysis, and stored, even after measurement, for use in future research or follow-up analysis. The clarity of our strategy and where we'll focus in the near future leads us to a conclusion about the next steps in what's been a disciplined capital deployment strategy. As of today, we've repurchased roughly 25% of our outstanding shares relative to when we started the program last November. Today, we commit to an additional share repurchase of $500 million under the authorization approved by the Board of Directors last year, which will take place in fiscal year 2024. This will still leave us with approximately $500 million in cash on our balance sheet, which we plan to prudently deploy in opportunities that will accelerate growth and enhance profitability over the coming years. Our plans for the remaining cash, which should be adequate for the next couple of years, will be in support of our strategic roadmap. This includes organic growth investments to meet the needs of ramping customer demand, cash deployment for structural investments to streamline the operations like rationalization of footprint and system upgrade implementation, as well as tuck-in acquisitions likely in the tens of millions of dollars range that provide durable recurring revenue and enhance our current portfolio of offerings in support of sample-to-data. And we believe it's prudent to have a couple hundred million dollars available to run the business. To be clear, we do remain active on the M&A front with an eye toward financially attractive and strategically compelling acquisitions that would enhance the value proposition and accelerate the growth of our unique sample management portfolio. But as the creator of this unique sample management and measurement capability, we're also the largest player providing this type of complete service and companies we target that will add to our capability are necessarily smaller and, though valuable, will not require cash beyond our current needs. While we're in a challenging macro environment over the short term, we're confident in our long-term potential. We serve high-growth markets with fundamental underpinnings for healthy expansion. 2024 will be a year of top-line growth and increased profitability driven by revenue expansion and significant operational improvements that will drive shareholder value. We're on a path to be the preeminent provider of high-quality samples and high-value data to the life sciences industry. Herman will provide more detail during his prepared remarks, but suffice it to say we expect to grow mid to high single digits in a market that's forecasted to be up low single digits or even declining slightly next year. At the same time, we're laser-focused on profitability enhancements and expect to see improvement from fiscal 23 to 24 on both the gross and operating margin lines. I want to reiterate how encouraged I am by our accomplishments in fiscal 2023 and the momentum we have as we head into 2024. We're incredibly well positioned in the markets we serve, and we're ready to outgrow the market as we convert more customers to our value offerings. I want to thank the entire Global Ascenta team for their contributions and tireless efforts over the past year. Before I turn it over to Herman, I want to make a brief comment about the governance changes we also announced today. As you know, the board continues to add directors to support the company's ongoing transformation strategy. And to that end, we're thrilled to announce the nominations of DDA Hirsch and Martin Madhouse to join our board at the 2024 Annual Meeting of Stockholders. DDA and Martin both possess strong life sciences leadership experience and have track records of creating stockholder value. We're excited to have their fresh perspectives, and I look forward to working closely with them in the new year. At this time, I'm pleased to introduce you to our new CFO, Herman Kudo. Herman joins us from BD, where he most recently served as Senior Vice President of Finance, overseeing segments, regions, FP&A, and operations. Since Herman joined us on the 16th of October, he's hit the ground running and has already begun to make great contributions to the team. We're fortunate to have him on board. And I'll now turn the call over to Herman. Thank you, Steve.
spk11: I want to start by saying how thrilled I am to be part of Ascenta. Over the past four weeks, I have worked closely with the leadership team, the finance team, and other stakeholders to get up to speed on the business. I have been impressed by what I have seen, and I am energized by the potential that we have as a company. I look forward to meeting our customers and shareholders in the coming weeks and months. With that, I now refer you back to the slide deck available on our website. Turning to slide seven for some highlights. Fourth quarter revenue was 172 million, up 25% year over year, and up 2% on an organic basis. Most notable contributors to growth include a record quarter in our large automated stores business, as well as continued strength in sample repository solutions. Consumables and Instruments, or CNI, remained a headwind to growth in the quarter. However, on a positive note, we did see sequential improvements as we moved from Q3 to Q4. Excluding the C&I business, our organic growth in the quarter was 6%. B Medical also performed well, delivering revenue of 29 million, up 10% sequentially. I am delighted to announce that our cost savings initiatives are on track, and the benefits were felt in the quarter. where we delivered non-GAAP EPS of 13 cents and adjusted EBITDA of 4.6%, reflecting continued momentum. In the quarter, we also benefited by approximately 5 cents or $5 million pre-tax from the reversal of a stock-based compensation accrual versus our Q4 guidance. This accrual favorably impacted net income and had no impact to adjusted EBITDA. Moving to the full year, fiscal year 2023 all in revenue of $665 million represented 20% growth. While organic growth declined 1% in the full year, when you exclude CNI, our organic growth was 5%, a strong performance relative to the market. For the full year, acquisitions contributed $127 million to revenue, including 113 million from B Medical. Fiscal 2023 non-GAAP EPS was 31 cents, and adjusted EBITDA margin finished at 4.6%. As we move from the first half of 2023 to the second half of 2023, we saw an acceleration in adjusted EBITDA margin of more than 300 basis points, largely driven by our cost savings initiatives. Turning to the balance sheet and capital deployment, we ended the year in a very strong position with $1.1 billion in cash, cash equivalents, and marketable securities, and no debt outstanding. Free cash flow was positive for the second quarter in a row at $30 million as we continue to focus on commercial execution and working capital management. For the full year, when you exclude certain payments in the first half of 2023 related to the divestiture, we delivered positive adjusted free cash flow of $14 million. In addition to the positive finish to fiscal year 23, I want to highlight to everyone that we have returned over $900 million to shareholders via our repurchase program as of today. This repurchase program has reduced the share count by over 19 million shares or by approximately 25% over the past year. Today, as Steve mentioned, we announced a commitment to repurchase an additional 500 million worth of shares in fiscal 2024, which will complete the 1.5 billion share repurchase authorization announced last year. We are extremely well positioned from a balance sheet perspective. And after this investment, we will still have roughly 500 million of cash on hand to be used for disciplined and long-term value creating initiatives. Now, let's turn to slide eight to take a deeper look at our results in the quarter. As previously mentioned, total revenue was 172 million, up 25% year over year. Non-GAAP gross margin was 42.8%, down 110 basis points. We did see positive gross margin expansion in the services and legacy Azenta product segments. The year-over-year favorability was largely driven by cost savings initiatives within operations and favorable product mix, namely in large automated stores. This favorability was offset by a soft B medical margin. I'm happy to report that in Q4, our cost savings initiatives within our operating expenses accelerated sequentially, and the benefits we expected to see in the P&L were realized. Non-GAAP operating margin was negative 0.5%, down 200 basis points year over year, primarily driven by the dynamics I just described. Again, non-GAAP earnings was $0.13 per share in the quarter. Now, let's turn to Slide 9 for a review of our Life Sciences products revenue and gross margin. Total segment revenue was $82 million for the quarter, up 70% year-over-year, driven primarily by acquisitions, which contributed $30 million. For the first time all year, the product segment returned to growth on an organic basis, up 3%. The performance was led by strong double-digit growth in large automated stores, partially offset by lower C&I sales. Excluding the C&I business, products was up 21% organically. Products' fourth quarter gross margin was 37.9% and down 230 basis points. year over year. Next, please turn to slide 10 for a review of our life sciences services segment, revenue and gross margin. The services segment delivered 90 million of revenue in the fourth quarter, an increase of 1% year over year. The organic revenue for the quarter was also up 1%, led by strength in sample repository solutions, partially offset by softness in genomics. In genomics, organic revenue declined 2% as we saw continued double-digit year-over-year growth in China, offset by softer revenue in the US. As you know, the genomics market overall continues to face pressures from macroeconomic uncertainty, pricing, and a difficult funding environment. In SRS, revenue growth was strong up 9% on an organic basis driven by the core storage business. The services business delivered 47.2% gross margin, up 140 basis points year over year, with improvements in both genomics and SRS businesses. Now, let's review the balance sheet in a little more detail on slide 11. Key areas to highlight are inventory and accounts receivable, where the improvement was primarily driven by the underlying performance of the business and our operations teams who have put in significant effort and are making good progress to reduce inventory balances as well as accounts receivable, both of which had become elevated during the COVID period. Let's turn to slide 12 to address the current period cash performance. Cash flow from operations was 40 million, primarily driven by the improvement in working capital. Capital expenditures for the quarter were $10 million. Let's turn to slide 13, where I want to remind everyone that starting in fiscal year 24, we will move to a three-segment structure, which consists of sample management solutions, multiomics, and B medical. Sample management solutions combines our sample repository solutions business as well as the product segment excluding B-Medical. Multiomics is the renamed genomics business. B-Medical will be reported in its own segment given its distinct end market dynamics and revenue cadence. We have provided much of the necessary information to model the new segments in the past disclosures as well as in the appendix of today's presentation. Now, let's turn to slide 14 for fiscal 2024 guidance. For the full year, we expect to deliver organic revenue growth in the range of 5 to 8% year over year, or $696 to $718 million. FX is currently expected to be a nominal headwind. By segment, we expect multi-omics to grow low to mid single digits, sample management solutions to grow mid to high single digits, and be medical to grow mid single digits. Growth will be driven by a combination of sales execution as the investments we made in our sales force begin to reach optimal productivity, broadening the use of channel partners in certain regions, expanding our geographic footprint, as well as by innovation and new product introductions as we develop new vectors of growth. As you look to model the OPEX line, please note you will see the expense come up as we reset our variable compensation levels to par as we enter the new fiscal year. We will also have some ad expense related to the Boston repository investment. We will, however, see offsetting benefits from the annualization of our cost initiatives completed in fiscal 23, along with the cost initiatives already identified that will start in the second fiscal quarter of 2024 and increase as we move throughout the year. While we are on the subject of operating expenses, I want to take a moment to recognize the numerous actions we have taken to improve our cost structure. which you can see in the EBITDA margin expansion from the first half to the second half of fiscal 23. And although we have taken actions to enhance our efficiency, we still have meaningful opportunity to optimize our expense structure. We look forward to sharing more on this in the future. As you can see on slide 15, on the adjusted EBITDA line, We expect EBITDA dollars to grow nearly 75% year-on-year. This translates to approximately 300 basis points of margin expansion versus fiscal 2023. This expansion reflects the impact of our cost initiatives as well as solid leverage on sales growth. The work we will do to further right-size our cost structure will positively impact both EBITDA dollars and margins. We expect EPS to be in a range of 19 to 29 cents per share. Our commitment to return capital back to shareholders through the completion of the initial 1 billion of share repurchases, as well as today's announcement for an incremental 500 million of share repurchases for fiscal 2024 is expected to reduce our average share count to approximately 52 million shares in fiscal 2024. However, our share buyback will also reduce interest income in fiscal 2024 to 27 to 29 million. The lower share count offset by the lower interest income creates a short-term net headwind of approximately 13 cents in fiscal year 24. In addition, we estimate the tax rate will increase to a range of 33% to 37%, which is an approximately $0.03 headwind year over year, largely driven by deferred tax assets that will not be realized related to stock-based compensation. If we remove the net impact of stock-based compensation, our effective tax rate would be comparable to 2023. And finally, with regard to cash flow, We expect capital expenditures of roughly $50 million in fiscal 2024, and we are highly focused on free cash flow generation and expect to be cash flow positive in the year. In terms of the quarterly guidance, please refer to page 16 of the slide deck for color and key considerations. We will provide this color every quarter and update our full year guidance based on what we are seeing. Excluding B-Medical, the business is expected to grow low single digits in the first quarter. Our current forecast for B-Medical anticipates a decline of approximately 75% year over year due to the timing of orders. In total, we expect Q1 revenue will decline mid-teens year over year. Notwithstanding Q1 softness in B Medical, it is important to anchor back to the full year where we feel very good about the 5% to 8% growth for Acenta. B Medical's expected mid-single-digit growth in fiscal 2024 is underscored by the opportunity in the Democratic Republic of Congo, which we just announced, and by itself could represent 50% or more of their full year revenue. We expect gross margin to be down in Q1 driven primarily by B medical. R&D expense as a percentage of revenue is expected to be around 6%, and SG&A as a percentage of revenue is expected to be at its highest point of the year and approaches the mid 40s. Keep in mind that Q1 reflects the full impact of the strategic sales investments while our additional cost savings initiatives ramp throughout the year starting in q2 overall we expect the business to be roughly break even on adjusted ebada and approximately a few pennies negative on non-gap eps for the quarter in closing we are pleased with our performance in fiscal 2023 and are especially optimistic about the progress we made in the business as we move through the second half of the year. Still, we know there is much work to be done. Our attention moving into fiscal year 2024 is on continued strong execution with an acute focus on accelerating our margin expansion initiatives, which we will be talking to you more about in the upcoming quarters. I also look forward to an analyst day early next year where we can lay out a framework for our longer-term strategy and financial goals. We are committed to delivering on our purpose, serving our customers, and enabling life sciences breakthroughs faster. This concludes our prepared remarks, and I now turn the call over to the operator for questions.
spk06: Thank you. If you would like to register a question, please press the one followed by the four on your telephone. you will hear a three-tone prompt to acknowledge that request. If your question has been answered and you would like to withdraw your registration, please press the one followed by the three. Once again, to register for a question, it is 1-4 on your telephone keypad. And your first question comes from the line of David Saxon with Needham. Your line is open.
spk03: Great. Hi, Steve. Hi, Herman. Thanks for taking my questions and congrats on the quarter. Maybe I'll start with a multipart question on multiomics or genomics, legacy genomics. So you called out weakness on pricing. It'd be great if you could break down, you know, the price versus volume contribution for growth in the quarter. You know, is any modality more impacted by pricing than the others? And then in terms of guidance, you know, obviously calls for some acceleration for multiomics. So maybe can you talk about the puts and takes for reaching the low single-digit growth floor versus getting to the mid-single-digit growth ceiling that's embedded in guidance? And then I'll have one follow-up. Thanks.
spk10: Okay, great. Hey, David, this is Steve Herman, and I'll share the response. Just a couple things. There's some pricing impact. I can't tell you exactly what it is, but we saw the similar growth across each of the elements, across NGS, across Sanger, and across Synthesis. So it seems to be a softness in the market as opposed to specifically pricing. But, you know, we sustained the, you know, revenue with just a really slight decrease, but we're battling for everything. There's no question about it. But I think the the volume of customer activity in each of the areas is depressed, and we're seeing that uniformly across. So it's not a single area of the omics business, but rather uniformly across. And without question, we're down in some of the small biotechs. I think everybody's feeling that, and we're certainly no exception. But there's a pricing differential of a few percentage points. for the compare year over year, for example, in NGS. And, you know, we're making up for a lot of that in volume, and we're continuing to maintain good margins in that business.
spk11: And, David, maybe it's Herman. Maybe I'll just add a couple of things. The pressure was probably worth about 50 basis points to margin in the quarter. But where I would like to anchor you on is when we talk about the guidance of low single digits. I think there's a couple things to think about. We do expect pricing pressure to continue into fiscal year 24, and we've cared for that in the guidance that we've given. But when you think about the Salesforce investments and the direct alignment, we feel good about the coverage that we now have, and those investments should start to pay off as the reps begin to hit their optimal productivity levels. We are expanding channel sales in places like Europe and Japan. And there's a really good innovation story here when we talk about things like AAV packaging and saying they're easy. And that's what gives us a lot of the confidence that we have in the low single digits that we described in the guidance.
spk03: Great. That's super helpful. Thanks for that. And then just on my follow-up on the B medical agreement with the DRC. So 60 million comes out of that. You know, B medical, obviously, you're calling to be down 75% in the first quarter. So does that project start to kick in in the fiscal second quarter or is it later? And then the 60 million that comes from that, is that all assumed in guidance or does that extend into Thanks so much for taking my question.
spk11: Yeah, so David, what I would say is, you know, we don't want to sit here today and predict the timing of when this is going to come in. It wouldn't be prudent for us to do that. We do think that we should have the ability to, as soon as the order comes in, fill whatever portion of it is requested. We do expect a lot of it to come in fiscal year 24 as we described. We have the inventory ready to go. So as soon as the order comes in, we will ship it. But right now to predict the timing on that, it wouldn't be wise for us to do that. There's a lot of moving parts to it. You know, what I would say is this. Think of it in terms of it's a pipeline, and we did have DRC in the pipeline, but it certainly wasn't at the magnitude that we're describing now. So it does bolster the pipeline quite a bit. So the way I would think about it is this order gives us a ton of confidence in the full year and probably gives us the ability to potentially do better than what we're currently describing.
spk01: Great. Thanks so much, everyone.
spk06: Your next question comes from line of Jacob Johnson with Stevens. Your line is open.
spk02: Hey, good evening. Can you have a nice quarter and thanks for taking the questions. Maybe just sticking on the B medical topic, I think revenues were up sequentially, but gross margins were down sequentially. Can you just help us understand kind of what drove that? Was it mixed? Was it something else? And then on the DRC contract, Is there any way to think about any impact that could have on B medical margins?
spk11: Yeah. So just in the quarter, you're right. There was a soft B medical gross margin. In the quarter, we took a precautionary warranty reserve for a component in our vaccine cold chain products. We have some work we need to do with the supplier to resolve a spec issue. It was a couple of million dollars. And what I would ask is keep in mind these products have a long warranty of up to 10 years. So we took it as a precautionary measure.
spk02: Got it. Thanks, Herman, and welcome, by the way. And then maybe for Steve, just on the large stores, you know, that was a standout again this quarter. You cited that backlog. Can you just kind of update us on where that backlog stands and then kind of any commentary around like new order trends? I guess, you know, large capital equipment's been an area that some have called out some softness in this quarter. So I'm just curious if you've seen any change there.
spk10: So we got, Jacob, we have roughly half of the year's forecast in backlog. So we continue to make good progress on the stores. You know, the pipeline is as robust as it's ever been. And so we're working to make sure that we continue to bring in enough business to keep it full. But, you know, we've always talked about the opportunity here beyond, you know, rare disease and population studies. We're, you know, putting large automated stores now into companies that manufacture biological materials. And that's helped us to drive another vector. So we feel good about the pipeline. We feel confident about the growth rate that we forecasted going into 2024. But, you know, healthy backlog right now, we continue to add to it. That's one part of the business we feel really strongly about, you know, continuing to be healthy in 2024. Got it. I'll leave it there.
spk02: Thanks for taking the questions.
spk09: Thanks, Jacob. Thanks, Jacob.
spk06: And your next question comes from the line of Andrew Cooper with Raymond James. Your line is open.
spk12: Hey, everybody. Thanks for the questions. And, Herman, good to chat with you here for the first time. um thanks andrew nice to meet you just on cni you know if i go back to last quarter there was some commentary around the instrument uh the instrument dynamics actually giving you a little bit of comfort that there was going to be considerable pull through things would would hopefully start to get better i don't think you put an exact timing on it but just maybe an update on to that thinking and how you think about potential for recovery in that business? Because obviously the product business is doing well other than that. So just would love to know kind of how you think about when that could normalize.
spk11: Yeah. Andrew, it's an interesting question. So I think where I would start, it's Herman, by the way. Sequential growth in CNI was 8.6% from Q3 to Q4. So we feel really good about that. As we speak with the teams, we do continue to hear that C&I budgets are constrained. But right now, we have the largest active funnel in this period than we've had at any point in the last calendar year. And when we dig a little bit deeper and we ask about what's going on with US distributor inventory levels right now, they tell us that they're basically at par where they need to be. We do hear that the levels in EMEA are a little bit lagging behind right now, but they do expect to cycle through that inventory by mid 2024.
spk12: Okay, great. That's helpful. And then maybe just another one on the large stores business, asking a little bit different way. Any changes there in terms of the sales cycles you're hearing about and the duration to close that backlog? just in terms of, obviously, a pressured funding environment for some of these customers.
spk10: There just aren't enough to give you the detailed trend here, Andrew, but for sure, the projects that have been out there are active. It often takes us 18 to 24 months from identification in order to closing it, so we're not seeing anything different from normal behaviors. But once a customer needs a store, we usually get moving pretty fast. And the indications we have usually start with the design work that we do up front. to get the specification close enough, and we think that activity is in normal course right now. So there's some reluctance for sure at some places, but then we focus on other stores where it's more active. So I can't tell you that it's different, but it's not overly robust, but it's certainly adequate for us to have a good look into 2024.
spk12: Okay, great.
spk09: I will stop there. I appreciate it. Thanks, Andrew.
spk06: Your next question comes from the line of Paul Knight with KeyBunk. Your line is open.
spk08: Yeah, I'm all for your time today. Steve, I guess I'll start with you first, though, and that is this SRS, the source business, is this the ramp up of some of these cell therapies and or the three PDUFA dates we're expecting here in December?
spk10: Yeah, Paul, so some of it, you know, it's difficult to say. I'll give you a number, Paul, that'll make sense. For us, the growth in the cell and gene therapy business for us has slowed this year compared to what we'd seen in the past, but we're up 7% year over year for the full year. But it's been slower, without question, it's been slower here in the third and fourth quarter. I will tell you, one of the things that we observed is for the first time in a few quarters, we had a multi-system order for the BioStor 3 cryosystems. It's been a little while since we had those. They used to come rather frequently. This is the first we've had probably in four quarters. So it's a good green shoot for us as people are starting to stabilize and make sense of which process is going to go forward or not. So I won't say it's off to the races yet, but it's a healthier environment for us. And the pipeline that we have continues to build in a way that we haven't seen now in a few quarters.
spk08: And Herman, you know, the seven or so percent EBITDA margin you're targeting on FY24 is a long way from peers. What has to happen there to get it better?
spk11: Yeah, I mean, listen, there is still work to be done, as I said in the prepared remarks. And, you know, listen, I'm going to come in here and And I'm an operator. I see the same things that everybody sees. And we need to work through that. And I look forward to talking more about that in the future. What I would say on the EBITDA margin that we put into the guide, we are seeing nice operating leverage on sales growth. So I'm happy to talk about that. We do expect gross margin to expand. despite price pressure and genomics and some of the investments that we're making in places like the Boston Repository. You see the cost initiatives that we've been talking about. They are showing up in the P&L. We have great line of sight to the Phase 2 initiatives that we've been talking about, so we feel really good about that. And I do want to remind everybody that the investments in the sales force, they do ramp in the first part of the year. and then the savings will happen throughout the year. So, again, listen, there's a lot to be done. We have work to do in this area. I do think we can be more efficient. We just have to work those plans, and we'll be happy to talk to you more about that in the future. Okay, thanks.
spk06: Your next question comes from the line of Vijay Kumar with Evercore ISI. Your line is open.
spk07: Hey, Vijay. Hey, guys. Thanks for taking my question. Hi, Steve. Hey, Vijay. I had a few questions, if you don't mind, Steve. One on this guidance here. So Q1 looks like we're looking at minus 15%. It's all being driven by B Medical. I think implied B Medical is $10 million revenues. What were orders for B medical in the quarter? Like why is B medical so low to start the year? And I think you mentioned multi-omics plus SRS is low singles. Is that assuming declines for multi-omics and what kind of declines are you expecting? Are you expecting China to grow in Q1?
spk10: So Vijay, there's a lot going on here. So let me give you a few. So the core business, we anticipate growth in Q1. the December quarter. So as you said, the decline comes from the B-Medical. And again, as Herman mentioned, we give you the forecast on B-Medical for where we are at this point in the quarter, just not knowing what else will come. But as we mentioned, the pipeline is particularly healthy. The expanded order from the DRC is particularly positive for us because we had some other We had a different forecast in the original pipeline, and now that they've upsized the order, this gives us great promise for what the year can be. So we're really confident about how we'll land for B Medical. We hope there's upside even to that number, but we feel confident about where we are. The timing of orders for the B Medical business, as you know, are unpredictable, and so we give you what we're holding at the moment. The pipeline is rich, and it doesn't mean things can't drop in between now and the end of the year. But, you know, we're not going to commit that yet until we hold it because a lot of things can happen. But, you know, the team is bullish. The order pipeline, the customer list is pretty significant, and we feel really strong about the opportunity growth for B Medical in the year. We're particularly enthusiastic about the strategic implications of the DRC order because of the ability now to handle biological samples, which is the reason, really the driving reason for us to be connected to DRC. be medical. So, vaccines out, human biosamples back. We think that's the start of what's going to be a tremendous value proposition for the customers.
spk11: So, Vijay, it's Herman. I think the way you're characterizing the Q1 orders, you have that pretty well figured out. When we think about Q1 growth in multiomics, I would point you to the full year range, and I would say The legacy genomics business is probably on the lower end, and SRS is probably on a little bit of the higher end as a way to think about it. So we do see growth on that side of the business.
spk10: And, Vijay, finally about China. You know, we don't give you the forecast there, but we still see really healthy environment in China. We recognize that's different from what other people are seeing. I'll give you a little extra color here. The genomics... The genomics growth of 12% was countered by a decrease in the product side. So the overall China growth was 2%. But we had 23% growth the prior quarter, 12% growth in Q4. It just continues to be a robust environment. A lot of that's because there are hundreds of companies within walking distance of our Suzhou facility. And so we have a really strong customer base. And if they need any kind of work, we're there for them. So it's a That's a customer capture proximity capability that allows us to remain really strong in China. And we anticipate that we'll outperform the market in China here in the first quarter.
spk07: Understood. Herman, welcome. One on the fiscal guidance here. I guess if DRC is adding $50 million, I think the implied B medical revenues for fiscal 24 is $125-ish. So XDRC, are we looking at base 75? Is that the right run rate for being medical? Just because DRC seems like outsized. I'm trying to understand, you know, being medical, what's the right run rate in exiting 24?
spk11: Yeah, I mean, Vijay, I would anchor you back to the guidance that we gave for being medical. I come back to the way I described it. We have a robust pipeline of This is a lumpy business. I think everybody knows that. The way the pipeline converts to revenue takes a little bit of time. We don't want to bet on it, but the DRC order certainly gives us a lot of confidence that the guide that we gave of mid-single digits for B Medical, we have a lot of confidence in that.
spk07: Understood. And Steve, maybe apologies for the multi-question here. Just one maybe on capital allocation here. I saw the new share repo announcement here. If I just look at the last interest income here, that's a pretty sizable EPS headwind. I'm just curious what drove the half a billion share repo when we knew that it was going to be an EPS headwind. Just curious on the back process here.
spk10: Yeah, Vijay, we've always been clear that managing the cash isn't, that's not our business. We're about, you know, growing the company. When we looked at the strategic alternatives we have in terms of acquisitions from organic growth first, then acquisitions and investments that we're making in the company to streamline, to reduce costs, to compress facilities, we really have adequate cash for the next couple of years, and we've been clear with the shareholders that if we don't have better use for cash, it belongs to them. And that's really what drove the decision. So we made a decision a year ago for $1.5 billion. We committed $1 billion. And we're simply following through on the remainder of that authorization from the board that we put out a year ago. So we'll still have $500 million of cash. We've got a lot of internal work to continue to improve the operations to get the profitability up. And that's how you'll see us focusing mostly Here over 2024, we've got a good path toward growth, and now we've got to get the profitability up, and that's how we'll make internal investments, organic investments, to make sure that we're able to deliver on that. And these are investments that a $700 million revenue company needs to be making now to make sure that we're a hugely profitable $2 billion revenue company, and that's really the focus that we have here in fiscal 24.
spk07: Understood. And Herman, one last one for you here. on EPS, that guidance. Is the tax rate there, should it normalize once these DTAs go away, or what's the normalized tax rate, and do you expect gross margins to be up next year?
spk11: Yeah, let me take the gross margin one first. Yeah, I do expect gross margin expansion next year, so we should certainly count on that. And what I would say is it's growing, And it's growing despite some investments that we're making. So the Boston repository would put pressure on margin. We talked about some of the pricing pressures we're seeing in genomics would put pressure on margin. But I think the big story is we do see volume. And with that volume coming in, we do expect leverage on our fixed overhead and labor efficiency. So we feel really good about that. Going to the tax rate, yeah, I mean, I would – anchor you back to where we were in 23 as sort of a more normalized tax rate. And in the prepared remarks, I think I alluded to if you remove this headwind, you do get back to that more normalized rate in that mid-20 range.
spk06: Thanks, guys.
spk09: Thanks, Vijay.
spk06: Your next question comes from the line of Yuan Shi with B. Reilly. Your line is open.
spk04: Hi, Tim. Congrats on a good culture and thank you for taking my questions. Hi, Sherman. Hi, Steve. Sorry about this multiple question here. For the guided organic growth of 5% to 8%, can you please clarify how much of it is contributed from B. Medical And then is the organic revenue growth in line with the overall industrial growth? Can you highlight the segment you think that grows higher than the industrial average? Thank you.
spk11: Yeah. I mean, let me start with a couple of things, and then, Steve, feel free to jump in. If you look at – I think maybe the best way to look at it is if you look at a Zenta – X acquisitions and X CNI, we grew 5% organically for the full year and 6% in the quarter. We did see sequential growth in CNI, which tells us that maybe we've cycled through these tough compares. Beyond that, when you think about the sales team investments, the channel expansion that we're doing, and the strong backlog that we have in stores, It gives us a lot of confidence in this five to eight that we've guided today. And on top of that, we are seeing, when you think about the stores business, we are seeing new vectors for growth. We're seeing companies who manufacture biological materials that are using our stores as part of their supply chain. So we have a lot of confidence in the five to eight. This is a tough market, and we do believe this five to eight represents us outperforming it.
spk10: And you want to answer your question a little bit about how do we compare with the market? It's tough for us because we don't have full year looks from people, and because we're off cycle here, our fiscal year started on October 1st. We look at peers and kind of what they're guiding for the quarter. We think in our core business we're outperforming. And just the momentum we've had and the bottoms-up look we have with the business, we're really comfortable with a 5% to 8%. If the market picks up beyond what we believe it looks like, we'll outperform that. We think we're set up to do that. We focus on our ability to outperform. We think the offerings we have are superior. And that's really how we've guided the business. On the product side and the services side, we remain positive. very competitive. And so we're imagining a slow growth market and that 5% to 8% growth would outgrow our current view of what the market is.
spk04: Got it. Thanks for that helpful color. And maybe one last question from me. For the remaining $500 million, do you see any long-term initiatives where you can invest or improve internally to improve the top line and product margins?
spk11: Yeah, it's Herman Yuan. Yeah, I do think there could be, as we start to build out our plans on how we expand EBITDA margin through what I would describe as operational-type programs, there could be the need to use some of that money. Certainly, that's a lot of money, $500 million, but use some of that money to build out some of those programs. And, you know, we're looking at architecture-type things that we want to think about. You know, maybe there's some product line focus that we could do, and then certainly continuing with the org efficiencies that we've already began.
spk10: And you want to put a couple in for you. You know, we made investments. We basically doubled the capacity we have in the Indianapolis area. We're putting a Boston biorepository in. We're about to open a genomics laboratory in Oxford in the U.K. We're developing next generation tools. So we are making organic investments from the top line standpoint, and those are already in place, and it's really to satisfy customer demand that we see coming, and also to transform some of the product areas where we're already market leaders, but we think we have product lines that will help to distance from even where we are today. So those will be top line value creators without question, and as Herman mentioned, other investments inside to rationalize footprint, to continue to reduce costs, to get systems implementations in place so that we're a much more profitable, much more efficient company as we go forward. So it's hard to earmark a full $500 million for that, but we've got a couple of things that strategically make sense. They're rather small tuck-ins, but they'll add to the strategic portfolio, and we think we have a good line of sight for how to keep growing the company with a significant balance sheet that has that $500 million on it.
spk01: Got it. Thank you.
spk06: And there are no further questions. I'll turn the call back to Steve Schwartz for closing remarks. Thank you.
spk10: Okay. Thank you, Operator. And thanks, everybody, for joining us today. Before we conclude, I just wanted to deliver a brief message of thanks to Lyndon Robertson, who most of you know now for quite some time. But over the past 10 years, Lyndon's been really an incredible partner to me as a collaborator and a teacher, and in doing so, really a tremendous value creator for all of us. He's been extraordinarily customer-focused, and by that I mean his end-to-end use customers, but also you, our investors and analysts. He's been a patient, detailed, precise communicator, and he's always been someone who delivered the messages with care, really with the sole intent to provide clarity to you. His focus was always on what was best for Azenta and for you, our shareholders. In every way, Lyndon's represented Brooks Automation and Azenta in a manner that made each of us proud to be part of his company, and we'll miss his presence and his leadership. Of course, we're enthusiastic about Herman as our new CFO, and I thank Herman and Lyndon for the means by which they've worked together during this transition period. It's been great for the company, particularly smooth, and I think you can tell from the Herman's ability to answer a myriad of questions that have come in already. He's 100% up to speed. And I just thank both of them for that transition. So that said, we really thank you for your support of Azenta. Herman and I look forward to seeing many of you at various upcoming investor meetings and certainly on our next earnings call in early 2024. So we thank everybody and look forward to speaking next time. Bye.
spk06: That does conclude the conference call for today. We thank you for your participation and ask that you please disconnect your line.
Disclaimer